Rainier's Margard Picks Goodrich, PathoGenesis on 'Rukeyser'
Bloomberg News
June 5, 1998, 7:47 p.m. PT
Rainier's Margard Picks Goodrich, PathoGenesis on 'Rukeyser'
Owings Mills, Maryland, June 5 (Bloomberg) -- B.F. Goodrich
Co. was among the companies recommended by James R. Margard,
chief of equity research at Rainier Investment Management, on
Public Broadcasting System's ''Wall Street Week With Louis
Rukeyser'' program.
Margard, who helps manage about $4.3 billion in assets, said
Goodrich appears to be taking a larger share of the jet parts
market and has ''very strong'' earnings growth.
BF Goodrich sold its automobile tire business 12 years ago
and is now supplying tires and entire jet systems for airplane-
makers including Boeing Co. and Airbus. Margard said the
company's earnings should grow about 28 percent this year and 19
percent next year. Goodrich had income from continuing operations
of $179.3 million, or $2.42 a diluted share, in 1997.
Margard also recommended biotechnology stocks for ''those
who can tolerate some risk.'' He recommended PathoGenesis Corp.
in particular, which has a ''fairly miraculous'' treatment for
cystic fibrosis, he said.
Margard, who trades stocks as well as picks them, said he
thinks the U.S. market is fairly valued and recommended mid-sized
companies over smaller ones because they seem to have the most
growth.
Among the panelists, Barbara Marcin, senior portfolio
manager at Citibank Global Asset Management, recommended
Halliburton Co., International Business Machines Corp., Compaq
Computer Corp. and industrial control maker Parker Hannifin Corp.
Robert Stovall, president of Stovall/Twenty-First Advisers
Inc. recommended IBM, Computer Associates International Inc. and
Compaq.
--Courtney Schlisserman in the New York newsroom (212) 318-2300 |
